Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06372899 · ClinicalTrials.gov registry record · NA

Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers

A NA study of Tobacco Use and Cigarette Smoking, sponsored by Abramson Cancer Center at Penn Medicine.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT06372899: Recruiting NA study of Tobacco Use and Cigarette Smoking, sponsored by Abramson Cancer Center at Penn Medicine.

NCT06372899 is a NA study of Tobacco Use and Cigarette Smoking that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 200 participants, below the 376-participant average among 76 other Tobacco Use trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06372899, a NA study of Tobacco Use and Cigarette Smoking, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

This between-subjects study aims to evaluate whether e-cigarettes (ECIGS) versus oral nicotine pouches (ONPS) more readily substitute for combustible cigarettes among 200 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to ECIGS or ONPS and be instructed to switch (versus smoking cigarettes) over a 6-week period. Relative reductions in biomarkers of exposure will be measured. ECIG- and ONP-associated subjective reward and the reinforcing value of ECIGS and ONPS relative to combustible cigarettes will be assessed as mechanisms.

Primary Outcome

The primary outcome is the longitudinal daily count of cigarettes from baseline to the end of the switch phase. Daily cigarette consumption will be determined by counting the daily spent cigarette filters returned for each of the 42 days (days 8 - 49).

Interventions

  • OTHER E-cigarettes
  • OTHER Oral nicotine pouches

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-10-02
Est. Completion 2028-03-31
Phase NA

What NCT06372899 shows while recruiting

NCT06372899 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 76 other Tobacco Use trials with a reported enrollment target (47% lower).

The record links to 4 conditions, with Tobacco Use appearing as the primary indexed condition, and to 2 interventions - of which E-cigarettes is the first listed.

NCT06372899 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06372899 about?

NCT06372899 is a clinical study titled "Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers". This between-subjects study aims to evaluate whether e-cigarettes (ECIGS) versus oral nicotine pouches (ONPS) more readily substitute for combustible cigarettes among 200 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to ECIGS or ONPS and be instr...

What is the current status of trial NCT06372899?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-10-02. Estimated completion is 2028-03-31.

What conditions does trial NCT06372899 study?

This clinical trial studies the following conditions: Tobacco Use, Cigarette Smoking, E-cigarette Use, Harm Reduction.

What interventions are being tested in trial NCT06372899?

The interventions under investigation include: E-cigarettes (OTHER), Oral nicotine pouches (OTHER).

Who is sponsoring clinical trial NCT06372899?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06372899 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06372899's enrollment target sits among peer trials

200 27th of 76 higher than 50 of 76 other Tobacco Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tobacco Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06372899, the US trial registry maintained by the National Library of Medicine. NCT06372899 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.